Does your workplace plan cover GLP-1s? How to actually find out.

Direct answer

Sometimes, and it depends far more on your employer’s plan design than on the insurer’s name on your card. For type 2 diabetes, most group plans we reviewed cover Ozempic (and now its generics) or Mounjaro after prior authorization. For weight management (Wegovy, Zepbound, Saxenda, Contrave), coverage is an optional category that employers choose to add or leave out. Where it is included, expect a special-authorization form with BMI criteria, renewal checks, and sometimes lifetime trial limits. In all three Prairie provinces, insurers also expect you to apply to the provincial program first where it applies.

Diabetes vs weight management: the rule that decides most claims

Insurers adjudicate GLP-1 claims by Health Canada–authorized indication. In plain terms:

Canada Life’s GLP-1 prior authorization form says it directly: “Ozempic, Rybelsus, and Mounjaro, are not covered for chronic weight management,” and “Wegovy is not covered under all benefit plans.” Sun Life’s public Ozempic form says Ozempic will not be reimbursed “when prescribed solely for weight loss.” So the first question is never “does my insurer cover Ozempic?” It is “which drug, for which indication, under my plan?” If you’re unsure of the difference between the molecules, see semaglutide vs tirzepatide in Canada.

What the big insurers publish

These carriers administer a large share of Prairie employer plans. What follows is what each one says publicly. Your plan sponsor (employer, union, or trust) can still choose different rules.

• Sun Life. Sun Life says obesity-management drugs are an optional drug category plan sponsors choose to include, managed either through prior authorization or an annual maximum. From 15 October 2024 it added anti-obesity medications to its Prior Authorization program for plans that cover them without a category maximum. Ozempic is in the prior authorization program. To check your plan, sign in to my Sun Life, go to Benefits, then Drug lookup; any required form shows under “Percentage covered.”
• Manulife. Manulife placed Ozempic on its prior authorization list on 5 April 2023. Its Wegovy prior authorization form (GL5197E) asks whether you have coverage under another group plan, whether a provincial program has approved or declined the drug, and states that completing the form “is not a guarantee of approval” and that form costs are the plan member’s responsibility.
• Canada Life. Ozempic and Rybelsus moved to prior authorization on 27 November 2023 and became eligible only for diabetes. Its GLP-1 form asks for an HbA1c of 7.0% or more and an inadequate response to, or contraindication to, metformin for type 2 diabetes requests. Wegovy requests need adjunct diet and activity, BMI, and comorbidity information. Use the Drug Search tool on My Canada Life at Work before your prescriber submits anything.
• GreenShield. GreenShield says weight-management drug coverage was added to its standard drug benefit for new groups from 1 January 2023, and Wegovy joined its Specialty Care Program in October 2024. GreenShield also says its formulary decisions do not override an employer’s choice, so “standard” does not mean your group has it.

How common is weight-loss coverage? An International Foundation of Employee Benefit Plans 2026 pulse survey of Canadian employers found 37% cover GLP-1 drugs for both diabetes and weight loss, up from 31% in 2025. That means most employers still don’t.

Saskatchewan: SK Blue Cross and the Drug Plan

Saskatchewan Blue Cross says its personal health plans will not cover Wegovy, and since 1 June 2024 Wegovy has been available with Special Authorization on some group plans, depending on the employer. Saxenda, Contrave and Xenical also need Special Authorization for new claimants on group plans that cover them. Key points for Regina, Saskatoon, Moose Jaw and Prince Albert employees:

• One form for weight management. New claimants use the Chronic Weight Management Prescription Drug Special Authorization Request. It asks whether you have coverage under another plan and whether you’ve applied for provincial coverage such as Exception Drug Status (EDS) under the Saskatchewan Drug Plan.
• Decision by letter. SK Blue Cross says members get a confirmation or denial letter, issued within five business days of its receipt of confirmation.
• Diabetes goes through EDS. For type 2 diabetes, Ozempic and generic semaglutide are SK Drug Plan EDS benefits. Your prescriber applies to the province, and your private plan may then help with the remaining deductible or co-payment, depending on its wording. See Ozempic EDS in Saskatchewan.
• Special Support. Saskatchewan’s Special Support Program is a voluntary, income-tested program that sets a family deductible and co-payment. If your drug costs are high relative to income, ask the Drug Plan (1-800-667-7581) and your insurer how the two interact.

Tirzepatide in SK: Mounjaro is generally not a Drug Plan or EDS benefit, so it’s private-plan or cash. Our Mounjaro cost in Saskatchewan page covers the cash side; the Saskatchewan hub has the overview.

Alberta: Alberta Blue Cross employer plans

Alberta doesn’t have a single public drug plan that automatically covers working-age adults, so for most employed Albertans in Calgary, Edmonton, Red Deer and Lethbridge, the employer plan is where GLP-1 coverage starts. Alberta Blue Cross publishes a dedicated weight-loss special authorization form for employer plans (ABC 60130, revised May 2026) covering Saxenda, Contrave, Wegovy and Zepbound. What it shows:

• Lifetime trial limit. The form states a “maximum of two trials per drug per lifetime is allowed regardless of failure to respond or if the patient stops therapy” early. Starting and stopping casually can use up coverage.
• BMI and comorbidity. Prescribers record pre-treatment BMI and weight. Adults with a BMI from 27 to under 30 must have a weight-related comorbidity and a record of previous weight-management attempts that didn’t work.
• Renewals need follow-up weights. Renewal requests ask for current body weight on the drug.
• “May or may not be approved.” The form says so on its face. It also only matters if your employer’s plan includes weight-loss drugs at all.

One real Alberta example: the Alberta School Employee Benefit Plan (ASEBP), whose special authorizations are processed with Alberta Blue Cross, says its plan covers Wegovy and Zepbound with special authorization. It sets an initial six-month period, then continued coverage if you maintain at least 5% weight loss from baseline, with annual renewal. It covers Ozempic and Mounjaro only for type 2 diabetes. Your plan may differ. For diabetes coverage on the public side (ADBL step therapy / special authorization), see Ozempic cost in Alberta. For weight management, see Wegovy in Alberta and Mounjaro and Zepbound in Alberta.

Manitoba: Pharmacare comes first

Manitoba is the province where coordination trips people up most. Manitoba Blue Cross explains that many drug plans follow the Manitoba Pharmacare formulary, so a drug that needs Exception Drug Status under Pharmacare often needs that EDS approval before the private plan pays. After approval, members upload the Pharmacare EDS letter so the plan can process claims.

• Register for Pharmacare even with benefits. Manitoba Blue Cross says it temporarily suspends drug payments once you reach a plan-specific dollar threshold, until you upload your Pharmacare registration letter. That protects the plan from paying for drugs Pharmacare would cover.
• Your plan’s payments count toward your deductible. Pharmacare deductibles are income-based. Manitoba Blue Cross says Pharmacare-eligible drugs it pays count toward your deductible, and Pharmacare covers 100% of eligible costs after that.
• Weight-management drugs are a private-plan question. Pharmacare EDS listings for semaglutide are for type 2 diabetes. Wegovy or Zepbound coverage in Winnipeg, Brandon, Steinbach or Thompson depends on your group plan including weight-management drugs.

Details: Ozempic and Manitoba Pharmacare EDS, Mounjaro cost in Manitoba, and the Manitoba hub.

What 2026 generics change

• Generic Ozempic. Apo-Semaglutide and Dr. Reddy’s semaglutide are marketed in Canada and listed on all three Prairie public formularies for type 2 diabetes. Saskatchewan Blue Cross says existing Ozempic special-authorization approvals were updated automatically to include them; ask your own insurer whether yours carried over. Plans with generic pricing may pay only up to the generic price if you choose brand. Full Prairie breakdown: generic Ozempic in SK, AB and MB.
• Generic Wegovy (Sevmia). Health Canada authorized Apotex’s Sevmia, a generic of Wegovy for chronic weight management, in June 2026. When we checked Health Canada’s Drug Product Database on 2 November 2026, its DIN (02569582) showed “Approved” but not yet “Marketed.” Once it’s marketed, plans that cover Wegovy may add it. It does not create weight-loss coverage on a plan that excludes weight-management drugs.
• Tirzepatide prices. No generic tirzepatide is available. Lilly’s submitted list prices for Mounjaro run about C$300 / C$420 / C$540 per pen by dose tier before pharmacy markup and dispensing, which is why plan coverage matters.

How to ask HR (copy-paste questions)

HR staff often don’t know drug-level detail, but they can get you the plan booklet or point you to the insurer. Ask for answers in writing or use the insurer’s drug look-up:

1. “Who is our group benefits carrier, and what is our plan / contract number?”
2. “Does our drug plan include weight-management (anti-obesity) drugs such as Wegovy or Zepbound, or are they excluded?”
3. “Is there prior authorization, an annual or lifetime maximum for that category, or a limit on the number of trials?”
4. “What’s our co-insurance and deductible for drugs, and do we use generic or lowest-cost pricing?”
5. “Does the plan require me to apply to the Saskatchewan Drug Plan EDS / Alberta program / Manitoba Pharmacare first?”
6. “Is there a Health Spending Account I can use for the gap, or for form-completion fees?”

You don’t need to share your diagnosis with HR. The insurer, not your employer, reviews prior-authorization medical details. Then sign in to your insurer’s member portal and search the drug by name or DIN. That’s the most reliable answer you’ll get before your prescriber fills out anything.

If you’re denied or not covered

• Ask which criterion wasn’t met. Incomplete forms are a common reason for denial. A resubmission with full history (BMI, comorbidities, prior treatments) may be reviewed differently. That’s not guaranteed.
• Check a second plan. If you’re also covered under a spouse’s plan, coordination of benefits may apply. Manulife’s form asks for the other plan’s decline notice.
• Price cash honestly. Call pharmacies with the DIN for an all-in quote, including the dispensing fee. Licensed Canadian telehealth services may also quote partner-pharmacy pricing. Compare in our provider directory.
• Keep receipts. Unreimbursed prescription costs may be claimable as medical expenses on your tax return. Check current CRA rules or ask a tax professional.
• Don’t chase “no-insurance-needed” shortcuts. Gray-market or “research use only” semaglutide and tirzepatide are not Health Canada–authorized products. Read buying semaglutide online in Canada first.

FAQ

Does workplace insurance cover Wegovy or Zepbound in Saskatchewan, Alberta or Manitoba?

Only if your employer’s plan includes weight-management drugs, which is optional. Sun Life calls obesity drugs an optional category plan sponsors choose. Saskatchewan Blue Cross covers Wegovy on some group plans with Special Authorization, and not on personal plans. Alberta Blue Cross has a weight-loss special authorization form for employer plans covering Wegovy and Zepbound. Check your insurer’s drug look-up or ask your plan administrator.

Will my group plan cover Ozempic for weight loss?

Generally no. Canada Life’s GLP-1 form says Ozempic, Rybelsus and Mounjaro are not covered for chronic weight management, and Sun Life’s Ozempic form says it is not reimbursed when prescribed solely for weight loss. Plans that cover weight management usually do it through Wegovy or Zepbound with special authorization. Ask your insurer what your plan allows.

Do I have to apply to the provincial drug plan before my private insurer?

Often yes, where a provincial program applies. Saskatchewan Blue Cross’s weight-management form asks whether you applied for Saskatchewan Drug Plan EDS. Canada Life tells members to apply to their provincial program where applicable. Manitoba Blue Cross says many plans follow the Pharmacare formulary and may suspend drug payments until you register for Pharmacare. Confirm the order with your insurer.

What does a GLP-1 prior authorization form ask for?

For type 2 diabetes, typically your diagnosis, HbA1c, and previous treatment such as metformin. For weight management, typically BMI (often 30 or more, or 27 or more with a weight-related condition), comorbidities, previous weight-management attempts, and use alongside diet and activity. Renewals often require documented weight loss. Alberta Blue Cross’s employer-plan form also limits each drug to two trials per lifetime. Completing a form never guarantees approval.

Does generic Wegovy mean my plan will now cover weight loss?

No. Health Canada authorized Sevmia, a generic of Wegovy, in June 2026, and as of 2 November 2026 the Drug Product Database showed it as approved but not yet marketed. A generic may lower the price on plans that already cover Wegovy, but it does not add weight-management coverage to a plan that excludes it. Check with your insurer.

Sources (re-check before you act)

• Canada Life — Drug Prior Authorization Form: Ozempic, Rybelsus, Wegovy, Mounjaro (M6453) · Canada Life notice: Ozempic and Rybelsus to prior authorization (Nov 2023)
• Sun Life — Prior authorization forms · Sun Life — Anti-obesity drugs added to Prior Authorization (Oct 2024) · Sun Life — The rise of obesity in Canada (report)
• Manulife — Wegovy Drug Prior Authorization form (GL5197E) · Manulife — Ozempic: what employers should know
• GreenShield — 2026 Drug Trends & Insights
• Saskatchewan Blue Cross — Coverage and Special Authorization for chronic weight management products · SK Blue Cross weight-management SA form
• Government of Saskatchewan — Special Support Program (Drug Cost Assistance)
• Alberta Blue Cross — Weight-loss special authorization request form for employer plans (ABC 60130) · ASEBP — Understanding your coverage for weight loss medications
• Manitoba Blue Cross — Member FAQ (Pharmacare, EDS) · Manitoba Pharmacare Program
• Health Canada — Canada approves first generic semaglutide for weight loss (June 2026) · Health Canada Drug Product Database
• IFEBP — GLP-1 Drugs: 2026 Pulse Survey (Canada)

Related: Generic Ozempic on the Prairies · Ozempic EDS in Saskatchewan · Wegovy in Alberta · Manitoba Pharmacare EDS · Felix vs Maple · Saskatchewan hub · Alberta hub · Manitoba hub.

Compare Prairie-serving providers → GLP-1 guide

Informational eligibility quiz Felix details May be affiliate Maple details May be affiliate